Vilon is a thymus-derived bioregulatory peptide commonly described as the dipeptide Lys–Glu (KE). It is studied for its potential immune-modulating effects, particularly in the context of thymus-related immune function and T-cell regulation. Research suggests Vilon may support immune cell differentiation, normalize cytokine signaling, and contribute to immune homeostasis. These properties make it relevant in studies involving immunosenescence, age-related immune decline, chronic inflammation, infection susceptibility, and immune dysfunction. By supporting balanced immune regulation rather than excessive stimulation, Vilon has become a peptide of interest in research focused on immune resilience, systemic vitality, and longevity-related immune restoration.

α-Klotho is a transmembrane and soluble endocrine protein first identified in 1997 and now widely recognized as a key candidate in aging biology. It is expressed predominantly in the kidney and choroid plexus of the brain, and its soluble form circulates in blood, urine, and cerebrospinal fluid. Membrane α-Klotho functions as an essential co-receptor for FGF23, regulating phosphate and vitamin D metabolism. Soluble α-Klotho is studied for its broader endocrine-like effects, including modulation of oxidative stress responses, inflammatory signaling, IGF-1 and mTOR pathways, and Wnt-associated tissue remodeling. Experimental models show that Klotho deficiency is linked to accelerated aging-like phenotypes such as vascular dysfunction, sarcopenia, cognitive decline, cardiac fibrosis, and osteopenia, while elevated Klotho expression is associated with improved cognition, delayed vascular aging, enhanced muscle regeneration, and increased lifespan. Due to its connection with senescence biology, SASP-driven inflammation, kidney decline, and neurodegenerative processes, α-Klotho remains a central molecule in research focused on longevity, metabolic regulation, and systemic resilience.